Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2021). On theSindex it has a DataRank of 0. It has been cited 2 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 7R01AI157046-03
Drug target validation of the enterovirus D68 2A protease
National Institutes of Health
Grant: 7R01AI147325-04
High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A proteases
National Institutes of Health
Grant: 5T32GM008804-05
CHEMICAL-BIOLOGY INTERFACE TRAINING GRANT
National Institutes of Health
Grant: 5R01AI158775-03
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals
Fields of Study
Keywords
Sustainable Development Goals